The development of technologically advanced products is one of the key driving factors for the HAI diagnostics market. Advancements in technology have resulted in the development of products that offer low turnaround time and reliable results. This has resulted in the development of molecular diagnostics as a separate niche, which is attracting many companies to invest in it. For instance, the cobas Liat PCR system with four assays was launched by Roche Diagnostics in 2017, which can conduct a 20-minute real-time PCR nucleic acid test for Clostridium difficile detection.
Request to Get the Sample Pages at:
The HAI diagnostics market is segmented by end user, product, region, test type, infection type, and application. Based on infection type, the classifications are hospital-acquired pneumonia, urinary tract infections (UTI), gastrointestinal infections, surgical site infections, and bloodstream infections. The UTI classification garnered the highest revenue of $829.0 million in 2017, and is expected to generate a revenue of $1,337.1 million by 2023. The Centers for Disease Control and Prevention mentioned that of all the cases of hospital-acquired UTIs, about 75.0% are associated with a urinary catheter.
Therefore, the market is set to advance in the forecast period due to technological advancements, growing geriatric population, and rising prevalence of HAIs in emerging economies as well.
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
This post was originally published on Crypto Coin Guardian